Papa John's Int'l, Inc. (NASDAQ:PZZA), a pizza restaurant operator, on Tuesday reported Q3 2014 financial results beating analyst estimates. Earnings for the quarter were $0.39 per share, up 22% from $0.32 per share in Q3 2013 and higher than the $0.37 Street estimate provided by Capital IQ. Revenues were $390.4 million, up 13% from $346.3 million reported for the same quarter last year and higher than the $379 million Street estimate. For full year 2014, the company expects diluted earnings per share to range from $1.68 to $1.74. The Street estimate on EPS was $1.74. Papa John's Int'l, Inc. (NASDAQ:PZZA) shares are trading in the 52-week range of $36.32 - $55.00.Exelixis, Inc. (NASDAQ:EXEL) posted mixed financial results for Q3, or the quarter ended Sept. 30, 2014, with a narrower loss than expected, while revenue fell short; the company also reported positive results from its E1512 trial. Exelixis, Inc. (NASDAQ:EXEL) shares are trading with a 52-week range of $1.35 - $8.41. The biotechnology company engaged in developing small molecule therapies for the treatment of cancer reported Q3 net loss of $62.6 million or $0.32 loss per share, compared with the prior-year period's $67.1 million or $0.36 loss per share. The Capital IQ analyst estimate is for $0.37 loss per share. Revenue was $6.3 million, up from $5.5 million in the same quarter last year. Analysts were expecting revenue of $6.77 million.Separately, EXEL reported positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type non-small cell lung cancer (NSCLC). The trial (Study E1512), which is sponsored by the U.S. National Cancer Institute (NCI) through a Cooperative Research and Development Agreement between the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, NCI and the company, met its primary endpoint.Exelixis President and CEO, Michael M. Morrissey, Ph.D., commented on the results: "This is one of the first substantial data sets from our collaboration with NCI-CTEP, which has enabled us to broaden the cabozantinib development program while focusing our internal resources on our pivotal trials. We are excited by these positive results and are looking forward to working with the trial investigators to support future development of cabozantinib in NSCLC and beyond, while we await top-line results from our pivotal phase 3 trial METEOR in metastatic renal cell carcinoma, now anticipated in the second quarter of 2015."Myriad Genetics, Inc. (NASDAQ:MYGN) posted Q1 results were in line with the Street view and its guidance for FY 2015 came in south of expectations Myriad reported Q1 diluted EPS of $0.21 and adjusted EPS of $0.25 along with revenue of $168.8 million. The Street expected $0.25 per share on $168 million in revenue, according to Capital IQ. The company is maintaining its fiscal year 2015 financial guidance and expects total revenue of $800 to $820 million and adjusted diluted earnings per share of $1.90 to $2.00. The Street is at $800 million in revenue and earnings of $1.90 per share. Myriad Genetics, Inc. (NASDAQ:MYGN) is projecting total revenues for Q2 2015 of $180 to $185 million and adjusted earnings per share of $0.33 to $0.36, diluted EPS of $0.30 to $0.33. The Street expects $193 million in revenue and $0.45 per share in earnings.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
